The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First report of the randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): JCOG2014 (ROBiTS).
 
Hironaga Satake
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Yusuke Suwa
No Relationships to Disclose
 
Takahiro Tsushima
Honoraria - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yasunobu Ishizuka
No Relationships to Disclose
 
Shogen Boku
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Taiho Pharmaceutical
Research Funding - Daiichi Sankyo Co. Ltd. (Inst)
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen - Local PI (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst)
 
Toshifumi Yamaguchi
Employment - Chugai Pharma; Ono Pharmaceutical; Yakult Honsha
 
Masako Asayama
Honoraria - Bayer; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Isofol Medical (Inst); SYSMX (Inst)
 
Mitsuru Yokota
No Relationships to Disclose
 
Koji Numata
No Relationships to Disclose
 
Takashi Ohta
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; EA Pharma; Eisai; Merck KGaA; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Research Funding - Takeda
 
Hisateru Yasui
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Yosuke Kito
Honoraria - Daiichi Sakyo; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yasumasa Takii
No Relationships to Disclose
 
Ryo Kitabayashi
No Relationships to Disclose
 
Yusuke Sano
No Relationships to Disclose
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; CMIC Co., Ltd.; Kyowa Kirin Co., Ltd.; m3.com
 
Tetsuya Hamaguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol Myers Squibb Foundation (Inst); Chugai Pharma (Inst); Incyte Japan (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Yukihide Kanemitsu
Honoraria - Covidien; Ethicon